Jade Biosciences (JBIO)
Developing antibody therapies for IgA nephropathy and systemic autoimmune diseases.
$21.43
At close+0.41 (+1.95%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.73
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Aug '25Aug '25Nov '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.86−$0.86−$0.48−$0.48−$0.45−$0.57−$0.76Pending
Estimate−$0.43−$0.43−$0.57−$0.57−$0.45−$0.52−$0.64−$0.73
Surprise−100.0%−100.0%+15.8%+15.8%0.0%−9.6%−19.4%—
RevenueReportedEstimate
Aug '25Aug '25Nov '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.73 | — | — |
| Aug 2026 | −$0.64 | −$0.76 | −19.4% |
| May 2026 | −$0.52 | −$0.57 | −9.6% |
| Mar 2026 | −$0.45 | −$0.45 | 0.0% |
| Nov 2025 | −$0.57 | −$0.48 | +15.8% |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| Aug 2025 | |||
| Apr 2025 | |||
| Mar 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.73 | — | — | — | — | — | — |
| Aug 10, 2026 | −$0.64 | −$0.76 | −19.4% | — | — | — | −1.1% |
| May 7, 2026 | −$0.52 | −$0.57 | −9.6% | — | — | — | +6.6% |
| Mar 6, 2026 | −$0.45 | −$0.45 | 0.0% | — | — | — | +2.7% |
| Nov 14, 2025 | −$0.57 | −$0.48 | +15.8% | — | — | — | +17.7% |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | |||||||
| Nov 13, 2025 | |||||||
| Aug 14, 2025 | |||||||
| Aug 13, 2025 | |||||||
| Apr 25, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Mar 14, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 13, 2024 | |||||||
| Mar 25, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 14, 2023 | |||||||